An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2018
At a glance
- Drugs Corticotropin (Primary)
- Indications Scleritis
- Focus Therapeutic Use
- Acronyms ATLAS
- 14 Aug 2018 Planned primary completion date changed from 30 May 2019 to 30 Sep 2019.
- 14 Aug 2018 Planned initiation date changed from 1 Mar 2018 to 15 Sep 2018.
- 16 Mar 2018 New trial record